Page 1,678«..1020..1,6771,6781,6791,680..1,6901,700..»

Audio: Air pollution tied to increased diabetes risk, study says | 89.3 … – 89.3 KPCC

Posted: February 10, 2017 at 11:40 am

A new study of overweight Latino children in Los Angeles finds exposure to air pollution may increase their risk of developing type 2 diabetes.

The USC study, published in the journal Diabetes,involved more than 300 Latino children, mostly in east Los Angeles, who were overweight or obese. Researchers regularly checked the children's glucose and insulin levelsover a period of years. The results indicated how well the cells in the pancreas that produce insulin were functioning.

The study found that among the children living in areas with higherlevels of nitrogen oxide and particulate matter, those cells were more inefficient, which put the youngsters at higher risk.

"We measured how badly [the insulin-producing cells] were deteriorating over time and that was our measure of progression towards type 2 diabetes," said Michael Goran,Director of USC's Childhood Obesity Research Center and a senior author of the study.

He said it's not yet clear how air pollution is affecting the functioning of the cells.

Other studies have examined the effect of air pollution on diabetes, but researchers say this is the first time a study has looked at effects on children over time.

Sung Kyun Park, who researches pollution at the University of Michigan's School of Public Health, called the study "very valuable and important."

Noting that the findings can only be generalized to overweight and obese Latino children, he said, "the next question is whether air pollution also impacts the person with a body mass index within the range of normal not overweight."

The number of people developing type 2 diabetes has risen in recent years, among them a growing number of children. Researchers have suggested that the increase is in part due to a rise in childhood obesity. The rate of diabetes is higher among Latinos.

Here is the original post:
Audio: Air pollution tied to increased diabetes risk, study says | 89.3 ... - 89.3 KPCC

Posted in Diabetes | Comments Off on Audio: Air pollution tied to increased diabetes risk, study says | 89.3 … – 89.3 KPCC

Diabetes can be harder on women – Portland Tribune

Posted: February 10, 2017 at 11:40 am

Everyone with diabetes needs to take care of his or her health, but women with diabetes face even more health challenges than their male counterparts.

Everyone with diabetes needs to take care of his or her health, but women with diabetes face even more health challenges than their male counterparts.

Diabetic women are more likely than diabetic men to have heart disease, kidney disease, poor blood-glucose control, high blood pressure, unhealthy cholesterol levels and obesity, said Melissa Jacobson, a diabetes educator with Legacy Weight and Diabetes Institute.

Lifestyle changes can help control type 2 diabetes, or insulin resistance, which accounts for about 95 percent of the 29 million Americans with diabetes, according to the American Diabetes Association.

The 1.25 million Americans with type 1 diabetes, however, have an autoimmune disease in which the pancreas stops producing insulin.

In terms of gender, diabetes is an equal opportunity disease striking as many men as women, Jacobson said. But women with diabetes have it worse than diabetic men, according to an article in Diabetes Forecast.

Although women usually live longer than men due to their lower rates of heart disease, women with diabetes have no such advantage. Women with diabetes are six times as likely to develop heart disease than women without diabetes. Men with diabetes are two to three times as likely to develop heart disease than their healthy counterparts.

Heart disease for women with diabetes is also more deadly than for diabetic men, Jacobson said, partly because heart attack symptoms for women fatigue, nausea, dizziness are more easily overlooked and dismissed than heart attack symptoms for men, such as chest pain.

Another general female health benefit higher levels of good cholesterol also disappears with diabetes, which drives down good cholesterol levels in women.

Kidney disease also is more common for women with diabetes than their male counterparts. Usually, men have a higher risk for kidney disease than women, and women who do get kidney disease usually don't get it until menopause. But women with diabetes are as likely as men to get kidney disease regardless of age.

Diabetic women are twice as likely to suffer from depression as diabetic men. Plus, when compared to women without diabetes, they are more likely to have polycystic ovary syndrome, more prone to urinary tract and vaginal infections (a persistent yeast infection can actually be a symptom of diabetes, Jacobson said), and more likely to have pregnancy complications.

In fact, merely having polycystic ovary syndrome is considered a risk factor for developing type 2 diabetes, Jacobson said. "That's a red flag," she said, adding that it usually takes 10 years for insulin resistance to even show up as type 2 diabetes.

Women with gestational diabetes, a form of diabetes that comes on during pregnancy and usually disappears after the baby is born, have up to a 60 percent risk of developing diabetes within 10 to 20 years, Jacobson added.

The key is to delay the onset of type 2 diabetes for as long as possible, especially considering the "tsunami of diabetes" forecast to hit the United States, she said.

Diabetes in the U.S. has increased a whopping 382 percent from 1988 to 2014, with one in 10 people having diabetes, according to the American Diabetes Association. One out of four of them don't know they have it because they have no symptoms. If this trend continues, one in every three US adults will have diabetes by 2050.

Jacobson encourages anyone with diabetes risk factors to request a fasting blood-glucose test during his or her next doctor's visit or to at least request a prediabetes screening.

"If you do something before it gets worse, you can reverse its effects," Jacobson said. "So much of it is how well people take care of themselves."

Link:
Diabetes can be harder on women - Portland Tribune

Posted in Diabetes | Comments Off on Diabetes can be harder on women – Portland Tribune

Why Cellect Biotechnology Ltd Shares Skyrocketed Higher Today – Fox Business

Posted: February 9, 2017 at 8:50 am

What happened

Cellect Biotechnology (NASDAQ: APOP) stock is up nearly 30% at 12:06 p.m. EST after the company announced that it treated the first patient in the biotech's phase 1/2 trial, dubbed ApoGraft01, testing its stem cell technology ApoGraft in patients with blood cancer.

Treating the first patient shouldn't have come as much of a surprise to investors. In November, the company said the Israeli Ministry of Health had given its approval to begin the trial. Perhaps investors are just really happy that the trial is finally starting. Also keep in mind that Cellect Biotechnology has a fairly low market cap, so the relative increase in valuation wasn't that much.

Image source: Getty Images.

Cellect Biotechnology's ApoGraft attempts to better select stem cells to help prevent graft-versus-host disease (GvHD), which occurs in 25% to 50% of recipients of allogeneic stem cell transplantation. GvHD happens when the donated stem cells produce immune cells that start mistakenly attacking the patients' normal cells because they see it as foreign. GvHD leads to 15% of the deaths that occur after allogeneic stem cell transplantation.

Continue Reading Below

ADVERTISEMENT

ApoGraft01 will enroll 12 patients, so it shouldn't take too long for Cellect Biotechnology to fully enroll the trial. Before data from that trial reads out, investors will get results from a trial testing ApoGraft in healthy volunteers by the end of the first quarter.

While Cellect Biotechnology is progressing, investors should proceed with caution given the biotech's precarious capital situation. At the end of September, Cellect Biotechnology had just $9.4 million in cash and cash equivalents on the books. The company may be able to raise additional capital, but most biotechs raise capital through secondary offerings, diluting shareholders' equity in the process.

10 stocks we like better than Cellect Biotechnology When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now and Cellect Biotechnology wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 6, 2017

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Read the original:
Why Cellect Biotechnology Ltd Shares Skyrocketed Higher Today - Fox Business

Posted in Biotechnology | Comments Off on Why Cellect Biotechnology Ltd Shares Skyrocketed Higher Today – Fox Business

Biotechnology xpert Jamie Metzl addresses realities of genetics revolution, Feb. 9 – Vail Daily News

Posted: February 9, 2017 at 8:50 am

Progressing at breakneck speed, genetic engineering has seen significant advancements since the first time Jamie Metzl addressed the topic at the Vail Symposium in 2015 to a sold-out audience. Metzl will return today, offering the latest update on the science and implications of this world-changing technology.

Metzl, an annual speaker at the Symposium, is a senior fellow of the Atlantic Council and an expert on Asian affairs and biotechnology policy. He previously served as executive vice president of the Asia Society, deputy staff director of the U.S. Senate Foreign Relations Committee, senior coordinator for International Public Information at the U.S. State Department, director for multilateral affairs on the National Security Council and as a human-rights officer for the United Nations in Cambodia.

Also a novelist, Metzl explores the challenging issues raised by new technologies and revolutionary science in his science fiction writing. His latest novel, Eternal Sonata, imagines a future global struggle to control the science of extreme human life extension. This world, according to Metzl, is not far off.

Jamie Metzl is a brilliant thinker and eloquent speaker who will be discussing a captivating subject based very much in reality, said Kris Sabel, Vail Symposium executive director. His background in biotechnology allows him to understand this complex science, his experience with international affairs lets him place science in a geopolitical context and his dynamic and creative mind can break it all down into digestible information for everyone

Here, Metzl elaborates on the progress of the genetics revolution, his new book, how this unique science fits into the landscape of technological breakthroughs and how the new administration may impact scientific progress.

VAIL SYMPOSIUM: What sort of progress has the genetics revolution made since you first addressed the issue in front of the Vail Symposium audience two years ago?

METZL: The genetics revolution is charging forward at a blistering, exponentially accelerating pace. Virtually every day, major progress is being made deciphering the genome; describing gene-editing tools to alter the genetic makeup of plants, animals or even humans; and outlining how gene drives can be used to push genetic changes across populations. Even if this rate of change slows, then its absolutely clear to me that these new technologies will transform health care in the short to medium term and alter our evolution as a species in the medium to long term.

VS: Despite your scholarly background on the topic, youve again chosen to use science fiction writing as a way to encompass real issues surrounding the progress in genetics science. How does your new book, Eternal Sonata, based in 2025, two years after the setting of your first genetics thriller, Genesis Code, reflect the true pace, opportunities and consequences of genetic science?

METZL: The genetic revolution is too important to be left only or even primarily to the experts. I write nonfiction articles and spend a lot of time with expert groups, but the general public must be an equal stakeholder in the dialogue about our genetic future. I aspire for my novels to be fun and exciting, but also to help people who might be a little afraid of science find a more accessible on-ramp to thinking about the many complex, challenging human issues associated with technological innovation.

I fully believe well be seeing significant growth in human health and lifespans throughout the coming decades, but this progress will also raise some thorny questions well need to address. Like Genesis Code, its based on real science and tries to explore what it will mean on a human level when new technologies begin to transform our understanding of our own mortality.

VS: How much weight should society put on concerns and opportunities of genetics science, or actually making conscious alterations to humans as a species?

METZL: Advances in genetic technologies will help us live longer, healthier, more robust lives, and we should all be very, very excited about that. Like all technologies, however, there will also be new opportunities for abuse. Thats why we need to have the broadest, most inclusive global dialogue possible to help us develop new norms and standards that can guide our actions going forward. The technologies are new, but the best values we will need to deploy to use them wisely are old.

VS: Has there, then, been any progress in policy to regulate genetics science or legal framework created to limit the radical changes this could have on society?

METZL: There is a real mismatch between the rapid pace of scientific advancement and the glacial pace of regulation. On the one hand, we dont want over-regulation killing this very promising field in its relative infancy. On the other, it is clear that all aspects of altering the human genome must be regulated. This challenge is all the greater because different countries have different belief systems and ethical traditions, so there is a deep need for a global norm-creation and then regulatory harmonization process.

VS: Do you have any insight on how changes in the administration will affect progress in this field of science?

METZL: Many people are worried about how the new administration will deal with these very complex scientific issues. Viewing genetic technologies in the context of the abortion debate would be a significant blow to this work in the United States. But the science is global, and even if the U.S. shuts down all of its labs for ideological or other reasons, then the science will advance elsewhere. Well lose our lead building the future as we wait forever for the coal mining and low-end manufacturing jobs to come back.

See the original post here:
Biotechnology xpert Jamie Metzl addresses realities of genetics revolution, Feb. 9 - Vail Daily News

Posted in Biotechnology | Comments Off on Biotechnology xpert Jamie Metzl addresses realities of genetics revolution, Feb. 9 – Vail Daily News

Registration Now Open for the 14th Annual BIO World Congress on … – Business Wire (press release)

Posted: February 9, 2017 at 8:49 am

WASHINGTON--(BUSINESS WIRE)--Today the Biotechnology Innovation Organization (BIO) announcedregistrationandhousingare now openfor the2017 World Congress on Industrial Biotechnology. The conference will be held July 23-26, 2017 at the Palais des congrs de Montral in Montral, Canada.

Now in its 14th year, BIO continues to bring new and exciting features to its annual World Congress on Industrial Biotechnology, stated Brent Erickson, Executive Vice President, Industrial and Environmental at BIO.Two new tracks-Flavors, Fragrances and Food Ingredients and Agricultural Crop Technologies and Biomass Supply-have been added to this years programming to represent the extended value chain of industrial biotechnology. Additionally, BIO brought The World Congress back to Montral so attendees from all over the world can gather and meet in one international location to make those important industry connections.

BIOs World Congress on Industrial Biotechnology is the worlds largest industrial biotechnology conference that brings together from across the globe business leaders, investors, academics and policymakers in the biofuels, biobased products, renewable chemicals, synthetic biology, food ingredients and biomass sectors. Industrial and environmental biotechnology is at the forefront of the biobased economy, generating good-paying jobs and making cleaner products and processes.

In 2016, the BIOWorld Congress on Industrial Biotechnologydrew around 907 industry leaders from 529 companies, 32 countries and 31 states, as well as the District of Columbia and hosted a record1,961 partnering meetings.

All programs at the World Congress on Industrial Biotechnology are open to attendance by members of the media. Complimentary media registration is available to editors and reporters working full time for print, broadcast or web publications with valid press credentials. For more information and to register, please visithttps://www.bio.org/events/conferences/world-congress-media

For more information on the conference please visithttp://www.bio.org/worldcongress. For assistance, please contactworldcongress@bio.org.

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces theBIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.BIOtechNOWis BIO's blog chronicling innovations transforming our world and the BIO Newsletter is the organizations bi-weekly email newsletter.Subscribe to the BIO Newsletter.

Upcoming BIO Events

BIO CEO & Investor Conference February 13-14, 2017 New York, NY

BIO Asia International Conference March 14-15, 2017 Tokyo, Japan

BIO-Europe Spring Conference March 20-22, 2017 Barcelona, Spain

Follow this link:
Registration Now Open for the 14th Annual BIO World Congress on ... - Business Wire (press release)

Posted in Biotechnology | Comments Off on Registration Now Open for the 14th Annual BIO World Congress on … – Business Wire (press release)

Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 on February 13 – Business Wire (press release)

Posted: February 9, 2017 at 8:49 am

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda, Ph.D., will present at the 19th Annual BIO CEO & Investor Conference 2017 on Monday, February 13, 2017, at 1:30 p.m. ET. The event will be held at the Waldorf-Astoria Hotel in New York, New York.

Interested parties can access a live audio webcast and slide presentation at http://www.aradigm.com. An archived presentation will be available on the Company's Web site for 30 days.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Aradigm is completing Phase 3 development of Pulmaquin (an investigational proprietary formulation of ciprofloxacin for inhalation) for the treatment of non-cystic fibrosis bronchiectasis. Aradigms inhaled ciprofloxacin formulations including Pulmaquin are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax. In addition, Aradigm has a pipeline composed of programs to prevent diseases in tobacco smokers through smoking cessation and a diagnostic program to detect aspirations of gastrointestinal fluid into the respiratory tract.

More information about Aradigm can be found at http://www.aradigm.com.

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.

Originally posted here:
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 on February 13 - Business Wire (press release)

Posted in Biotechnology | Comments Off on Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 on February 13 – Business Wire (press release)

Puma Biotechnology Inc (PBYI) Soars 10.04% on February 08 – Equities.com

Posted: February 9, 2017 at 8:49 am

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) had a good day on the market for Wednesday February 08 as shares jumped 10.04% to close at $37.25. About 1.21 million shares traded hands on 9,871 trades for the day, compared with an average daily volume of 966,951 shares out of a total float of 36.82 million. After opening the trading day at $33.85, shares of Puma Biotechnology Inc stayed within a range of $38.85 to $33.65.

With today's gains, Puma Biotechnology Inc now has a market cap of $1.37 billion. Shares of Puma Biotechnology Inc have been trading within a range of $73.27 and $19.74 over the last year, and it had a 50-day SMA of $35.29 and a 200-day SMA of $41.41.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 156 employees. Its CEO is Alan H. Auerbach.

For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

More:
Puma Biotechnology Inc (PBYI) Soars 10.04% on February 08 - Equities.com

Posted in Biotechnology | Comments Off on Puma Biotechnology Inc (PBYI) Soars 10.04% on February 08 – Equities.com

Animal Biotechnology Technologies, Markets and Companies 2017 – Research and Markets – Yahoo Finance

Posted: February 9, 2017 at 8:49 am

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of Jain PharmaBiotech's new report "Animal Biotechnology - Technologies, Markets and Companies" to their offering.

This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics is important in the application of biotechnology to manage genetic disorders and improve animal breeding. Genomics, proteomics and bioinformatics are also being applied to animal biotechnology.

Transgenic technologies are used for improving milk production and the meat in farm animals as well as for creating models of human diseases. Transgenic animals are used for the production of proteins for human medical use. Biotechnology is applied to facilitate xenotransplantation from animals to humans. Genetic engineering is done in farm animals and nuclear transfer technology has become an important and preferred method for cloning animals. There is discussion of in vitro meat production by culture.

Biotechnology has potential applications in the management of several animal diseases such as foot-and-mouth disease, classical swine fever, avian flu and bovine spongiform encephalopathy. The most important biotechnology-based products consist of vaccines, particularly genetically engineered or DNA vaccines. Gene therapy for diseases of pet animals is a fast developing area because many of the technologies used in clinical trials humans were developed in animals and many of the diseases of cats and dogs are similar to those in humans.RNA interference technology is now being applied for research in veterinary medicine.

Molecular diagnosis is assuming an important place in veterinary practice. Polymerase chain reaction and its modifications are considered to be important. Fluorescent in situ hybridization and enzyme-linked immunosorbent assays are also widely used. Newer biochip-based technologies and biosensors are also finding their way in veterinary diagnostics.

Biotechnology products are approved by the Center for Veterinary Medicine of the FDA. Regulatory issues relevant to animal biotechnology are described.

Approximately 124 companies have been identified to be involved in animal biotechnology and are profiled in the report. These are a mix of animal healthcare companies and biotechnology companies. Top companies in this area are identified and ranked. Information is given about the research activities of 11 veterinary and livestock research institutes. Important 108 collaborations in this area are shown.

Share of biotechnology-based products and services in 2015 is analyzed and the market is projected to 2025.

The text is supplemented with 35 tables and 5 figures.Selected 260 references from the literature are appended.

Key Topics Covered:

Executive Summary

1. Introduction to Animal Biotechnology

2. Application of Biotechnology in Animals

3. A Biotechnology Perspective of Animals Diseases

4. Molecular Diagnostics in Animals

5. Biotechnology-based Veterinary Medicine

6. Research in Animal Biotechnology

7. Animal Biotechnology Markets

8. Regulatory issues

9. Companies Involved in Animal Biotechnology

10. References

For more information about this report visit http://www.researchandmarkets.com/research/b9fmth/animal

View source version on businesswire.com: http://www.businesswire.com/news/home/20170203005322/en/

See the rest here:
Animal Biotechnology Technologies, Markets and Companies 2017 - Research and Markets - Yahoo Finance

Posted in Biotechnology | Comments Off on Animal Biotechnology Technologies, Markets and Companies 2017 – Research and Markets – Yahoo Finance

Center For Cell & Gene Therapy – Cell Therapy

Posted: February 9, 2017 at 8:47 am

1102 Bates Street, Suite 1670

Houston, Texas 77030

The GMP Facilities at the Center for Cell and Gene Therapy at Baylor College of Medicine are among the largest and most modern in the United States. Manufacturing of therapeutic biologics has existed at Baylor for more than twenty years, and is now centralized in 19,000 square feet on the 16th floor of the Feigin Center at Texas Childrens Hospital.

This facility opened in 2010 and contains 22 ISO 7 clean room suites supported by dedicated space for cell and product cold storage, flow cytometric analysis, quality control testing, data management and storage and quality assurance activities. The staff has extensive experience in GMP manufacturing of a wide variety of products and intermediates for cellular therapies and of viral and non-viral vectors, and master and working cell banks.

Manufacturing and testing supports more than 30 investigator-sponsored INDs conducted at the Texas Medical Center and institutions around the United States. Products have also been prepared under contract for researchers in Europe, Asia and Australia. The range of products that have been manufactured is shown under the Vector and Cell Therapy Facilitypages.

The facility is also accredited by the Foundation for the Accreditation of Cellular Therapy (FACT)and is CLIA registered for high complexity testing.

Center for Cell & Gene Therapy - cGMP Facilities

Link:
Center For Cell & Gene Therapy - Cell Therapy

Posted in Cell Therapy | Comments Off on Center For Cell & Gene Therapy – Cell Therapy

Cellectis gets US ok to test its universal donor cancer cell therapy – BioPharma-Reporter.com

Posted: February 9, 2017 at 8:47 am

US regulators have cleared French biotech Cellectis to trial its off-the-shelf blood cancer cell therapy, UCART123.

The product consists of T-cells modified to target the CD123 antigen on the surface of cancerous cells.

Jennifer Moore, VP of Communications at Cellectis, told us: "CELLforCURE, the largest commercial industrial facility for the production of innovative therapeutic cell therapies in Europe, a subsidiary of the biopharmaceutical group LFB, will perform the cGMP manufacturing of clinical batches of Cellectis allogeneic CART cells."

Unlike autologous cell therapies that are made from the specific patients own cells, UCART123 is composed of lymphocytes harvested from an unrelated, so called universal donor.

The advantage of this allogenic approach is that developers can make and store stocks of cell therapies rather than having to produce a specific batch for each patient, which makes such treatments cheaper according to Loan Hoang-Sayag, Cellectis Chief Medical Officer.

Hoang-Sayag said: Cellectis allogeneic UCART products have the potential to create an important shift with regard to availability, and cost-effectiveness, to make these therapies widely accessible to patient population across the world.

Gene editing

UCART123 - which Cellectis claims is the first allogenic cell therapy to be approved for trials by the US Food and Drug Administration (FDA) -will be tested as a treatment for patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The Phase I clinical studies due to start in the first half of the year.

Like other therapies in Cellectis pipeline, UCART123 is produced using Talen gene editing to inset genes that encode a chimeric antigen receptor (CAR) that targets the CD123 antigen.

The gene editing method is also used to prevent the T-cells of which UCART123 is composed from interacting with non-target proteins, thereby reducing side-effects

UCART therapies

One of Cellectis UCART therapies was used to successfully treat a baby girl with leukaemia whose disease had progressed despite chemotherapy.

According to the results of a study published in 2015 , the girl received a single dose (4.5x106/kg) of Cellectis allogeneic engineered T-cell product UCART19 and two months later the girl was cleared of leukaemia.

Original post:
Cellectis gets US ok to test its universal donor cancer cell therapy - BioPharma-Reporter.com

Posted in Cell Therapy | Comments Off on Cellectis gets US ok to test its universal donor cancer cell therapy – BioPharma-Reporter.com

Page 1,678«..1020..1,6771,6781,6791,680..1,6901,700..»